Breakthrough depression is a common problem in the treatment of bipolar disorder. Only one, recently published, double-blind, placebo-controlled trial has examined the efficacy of divalproex in the prevention of depressive episodes in bipolar patients. This report describes, in further detail, the findings from that trial of the effect of divalproex on multiple dimensions of depressive morbidity in bipolar disorder. A randomized, double-blind, parallel-group, multicenter study was conducted over a 52-week maintenance period. Bipolar I patients, who may have been treated with open-label lithium or divalproex and who met recovery criteria within 3 months of onset of an index manic episode, were randomized to maintenance treatment with divalproex, lithium, or placebo in a 2 : 1 : 1 ratio. Adjunctive paroxetine or sertraline for breakthrough depression was allowed in maintenance phase. Outcome measures were the rate of early discontinuation for depression, time to depressive relapse, proportion of patients with depressive relapse, mean change in Depressive Syndrome Scale score, proportion of patients receiving antidepressants, and time in the study. Among patients taking an antidepressant, a higher percentage of patients on placebo than divalproex discontinued early for depression. Patients who were previously hospitalized for affective episodes or took divalproex in the open period relapsed later on divalproex than on lithium during the maintenance period. Divalproex-treated patients had less worsening of depressive symptoms than lithium-treated patients during maintenance. Indices of severity of prestudy illness course predicted worse outcome in all treatment groups. Divalproex improved several dimensions of depressive morbidity and reduced the probability of depressive relapse in bipolar disorder, particularly in patients who had responded to divalproex when manic, and among patients with a more severe course of illness.
INTRODUCTION
Breakthrough depression is a common problem in the treatment of bipolar disorder. Double-blind, placebo-controlled studies conducted during the 1970s demonstrated that lithium was more effective than placebo at preventing recurrences of bipolar depression (Prien et al, 1973a; Fieve et al, 1976; Goodwin and Jamison, 1990) . A later, naturalistic study revealed that approximately 30% of lithium-treated bipolar patients experienced depressive relapse yearly (O'Connell et al, 1991) . Lithium has been found to be more effective in the maintenance treatment of 'classical' rather than 'nonclassical' bipolar disorder (Greil et al, 1998) , and less effective in rapid cycling, for which several anticonvulsants appear to be more effective (Dunner and Fieve, 1974; Bauer et al, 1994; Calabrese et al, 2000) . Antidepressants are frequently prescribed for bipolar depression prophylaxis (Zarate et al, 1995) ; however, their use is controversial because they may induce mood destabilization (Altshuler et al, 1995) . Therefore, additional medications to prevent breakthrough depression and reduce depressive morbidity are needed. Valproate may be useful in acute and prophylactic treatment of bipolar depression (Petty et al, 1999; Puzynski and Klosiewicz, 1984; Emrich et al, 1983) . In open-label maintenance trials (McElroy et al, 1988; Calabrese and Delucchi, 1990; Ghaemi and Goodwin, 2001) , valproate treatment reduced depressive symptoms in bipolar patients.
We previously reported the results of the first multicenter, double-blind, placebo-controlled trial comparing divalproex, lithium, and placebo for the prevention of affective episodes in bipolar I patients , presenting preliminary evidence that divalproex ameliorated depressive morbidity. This paper presents additional analyses from that study, including a comparison of the maintenance efficacy of divalproex, lithium, or placebo for bipolar depression. We hypothesized that divalproex would be more effective than placebo or lithium in reducing depressive morbidity of bipolar patients, especially those with a more severe course of illness prior to study entry because severity of illness course (number of previous affective episodes and/or hospitalizations) has been shown to reduce the effectiveness of lithium (Swann et al, 1999 Prien et al, 1974; Maj et al, 1998; Gelenberg et al, 1989) , but not of divalproex (Swann et al, 1999 .
PATIENTS AND METHODS
Methodology for this study has previously been described in detail .
Patients
Patients between 18 and 75 years old with bipolar disorder type I, confirmed by the Structured Clinical Interview for DSM-III-R (Spitzer et al, 1990) , were eligible for enrollment in the study. All patients experienced a manic episode (index episode) p3 months before randomization and at least one additional episode within 3 years before study entry. Patients with a history of substance dependence, substance abuse within 6 months before study entry, or severe medical conditions were excluded. Patients provided written informed consent for study participation. The study was approved by the Institutional Review Boards of each participating center.
Experimental Design
This was a randomized, double-blind, placebo-controlled, parallel-design, multicenter study that was comprised of two periods. The first was an open-label period that lasted up to 90 days, which was followed by a 52-week randomized maintenance period. During the open-label period, the index manic episode was stabilized with the investigator's choice of medication(s). Psychotropic medications, other than lithium or valproate, were discontinued before randomization. At the end of the open-label treatment period, eligible patients were randomized, in a 2 : 1 : 1 ratio, to divalproex (n ¼ 187), lithium (n ¼ 91), or placebo (n ¼ 94). Randomization requirements included a Global Assessment Scale (GAS) score 460, a Mania Rating Scale (MRS) score (derived from the Schedule for Affective Disorders-Change Version (SADS-C)) (Endicott and Spitzer, 1978 ) p11, and a Depressive Syndrome Scale (DSS) score (derived from SADS-C) o14. All criteria had to be met on two consecutive visits, at least 6 days apart.
During the first 2 weeks of the maintenance period, openlabel divalproex or lithium was withdrawn concomitantly with the upward dosage titration of the blinded medications (to achieve serum trough concentrations of 71-125 mg/l for valproate and 0.8-1.2 mEq/l for lithium). Patients were seen weekly for the first 6 weeks, then biweekly until week 12, and monthly thereafter.
Symptom severity was assessed using the DSS and MRS from the SADS-C (Endicott and Spitzer, 1978; Bowden et al, 1994) .
During the first month of maintenance therapy, use of lorazepam (for 2 weeks) and, if necessary, haloperidol (during the second week of lorazepam use) was permitted. A second course (p7 days) of lorazepam was permitted after the first month. Patients developing depression (DSS score X25) could receive adjunctive sertraline or paroxetine and were permitted to continue in the study.
Efficacy Outcomes
Outcome measures that were established a priori included rate of early discontinuation for depression, time to depressive relapse, proportion of patients with depressive relapses, mean change in DSS score from baseline, proportion of patients receiving adjunctive antidepressants, and time in the study. A depressive episode was defined by either need for antidepressant treatment (which should have been initiated in patients with a DSS score X25) or early discontinuation for depression (including SADS-C suicide item score X4, attempted suicide, or hospitalization for depression). This definition of breakthrough depression is not the same as that for a DSM IV episode of major depression (American Psychiatric Association, 1994) . The subgroup of patients who received an SSRI was evaluated on a post hoc basis.
STATISTICAL ANALYSES
All tests were two-tailed; analyses were performed using the SAS System, Version 6 (SAS Institute, 1989) . Values of Pp0.05 were considered significant.
Baseline comparability among treatment groups for demographic characteristics was assessed by the overall Ftest of the one-way analysis of variance (ANOVA) for age and by Fisher's exact test extended to R Â C for gender and race. For psychiatric history variables, comparability among treatment groups was assessed by the Kruskal-Wallis test for age at first manic episode and age at first depressive episode, and by the Cochran-Mantel-Haenszel test of equal row means for the number of prior manic episodes, number of prior depressive episodes, and the number of prior psychiatric hospitalizations. Fisher's exact test was used to test for pairwise group differences in proportion of patients using divalproex or lithium in the open period, hospitalized for the index episode, prematurely discontinuing from the study, and treated with sertraline or paroxetine (selective serotonin reuptake inhibitors, SSRIs) during the study. Number of days that patients used SSRIs and number of days that patients remained in the study was assessed by one-way ANOVA. For patients who used SSRIs, treatment differences in mean change from baseline DSS score to last DSS score prior to first use of SSRIs were evaluated by oneway ANOVA. Treatment differences in mean treatment day at first use of SSRIs were evaluated by one-way ANOVA.
Survival analysis of time to depressive relapse was performed for the intent-to-treat (ITT) sample (all patients receiving at least one dose of study drug). Life-table methods were used to compare survival curves using the Wilcoxon test because of its sensitivity to early group differences.
Logistic regression was performed for several dichotomous variables, including early discontinuation for depression, occurrence of a depressive episode, and SSRI use. Predictors were treatment group, sex, age, type of manic symptom cluster (classic vs dysphoric) in the open phase, baseline MRS score, baseline DSS score, lifetime number of depressive episodes (categorized 0, 1-5, 6-10, 11-15, 16-20, 420) , lifetime number of manic and depressive episodes, lifetime number of psychiatric hospitalizations (categorized as for depressive episodes), and age at first manic episode. Best subsets selection was used to identify a model based on score statistic (SAS Institute, 1989) .
Multiple regression was used to evaluate change from baseline for mean DSS score. Predictors were treatment group, sex, age, type of manic symptom cluster (classic vs dysphoric) in the open phase, baseline MRS score, baseline DSS score, lifetime number of depressive episodes, lifetime number of manic episodes, lifetime number of psychiatric hospitalizations, and age at first manic episode. Best subsets regression was used to identify a model using Mallow's cp statistic (a function of R 2 ) as the criterion (Draper and Smith, 1981) .
RESULTS

Baseline Demography and Clinical Characteristics
In all, 571 patients were enrolled in the open phase of the study; and 372 patients were randomized to maintenance treatment. Of the 199 patients who were not randomized, 51 used lithium only, 80 used divalproex only, 28 used both, and 40 used neither in the open study phase. No significant differences existed between randomized treatment groups for age, gender, or baseline clinical characteristics. The mean (SD) age of the study population was 39.2 (11.8) years old with similar numbers of men and women. Approximately half gave a history of 11 to 420 manic episodes and depressive episodes, with the first episode at a mean (SD) age of 24.5 (10.6) and 21.5 (10.0) years old, respectively. In all, 61% had at least one previous psychiatric hospitalization and 18% were hospitalized for the index manic episode .
In the open period, 40% (149) were treated with divalproex and 38% (142) with lithium; rates of use of divalproex or lithium did not differ across randomized treatment groups. Additionally, the number of days in the open phase (mean of 36.4 days across treatment groups) and the number of days from onset of the index episode to randomization (mean of 74.1 days across treatment groups) were equivalent in the randomized groups .
Early Discontinuation for Depression
The number of patients who suffered breakthrough depression during their participation in the maintenance, doubleblind phase of the study is presented in Table 1 . As previously reported, a lower percentage of divalproextreated (6.4%, 12/187) than placebo-treated (16.0%, 15/94) patients discontinued for depression (P ¼ 0.017 Fisher's exact test) . The rate of early discontinuation because of depression for lithium (9.9%, 9/91) did not differ from that of placebo or divalproex. The same trend was observed when early discontinuation data were analyzed by SSRI use. Among those treated with a SSRI for breakthrough depression, a lower percentage of patients in the divalproex group (9.8%, 4/41) discontinued early for depression than in the placebo group (45%, 9/20, P ¼ 0.003 Fisher's exact test) (Figure 1 ). Mean change from baseline in DSS score to the time of first SSRI use and rates of SSRI use did not differ in divalproex-, placebo-, and lithium-treated patients (Table 2 ). However, patients in the lithium group required an SSRI addition significantly sooner following randomization than those in the divalproex group ( . Similarly, the rate of early discontinuation for any reason was lower among patients in the divalproex group taking an SSRI than among patients in the placebo group taking an SSRI (56% [23/41] vs 85% [17/20], P ¼ 0.043 by Fisher's exact test). Rate of early discontinuation for any reason did not differ between the lithium and the SSRI group (71.4%, 15/21) and the divalproex and SSRI groups or the placebo and SSRI groups.
Divalproex-and SSRI-treated patients remained in the study significantly longer than placebo-and SSRI-treated patients (243.0 7 130.6 vs 168.8 7 130.6, F ¼ 4.27; df ¼ 1,79, P ¼ 0.044). The difference in length of time in the study between the divalproex/SSRI and placebo/SSRI groups was not attributable to mania relapse, as only one patient (in the divalproex group) had a manic episode while treated with an SSRI. The time in study prior to the addition of an SSRI (Table 2) . Among patients treated with an SSRI, the mean DSS score at the last assessment prior to initiation of the antidepressant was consistently greater than that measured 2, 4, and 8 weeks (LOCF) thereafter. The decrease in the mean DSS score was consistently greater (up to five-fold) among patients in the active treatment groups who completed the trial as compared to those who prematurely discontinued their participation for any reason (Table 3 ). The mean MRS score at the last evaluation before the initiation of antidepressant treatment was 0.8, 1.3, and 5.8 for patients who completed the trial in the divalproex, placebo, and lithium groups, respectively, and 1.5, 2.4, and 0.7 for patients who dropped out prematurely for any reason in the respective treatment groups.
Predictors of Early Discontinuation for Depression
Divalproex-treated patients were less likely than placebotreated patients to discontinue early for depression (OR ¼ 0.426 [0.182, 0.997], df ¼ 1, P ¼ 0.049). Neither mean baseline DSS score (4.6 7 4.6, 4.5 7 4.6, and 5.3 7 4.2, respectively) nor mean baseline MRS score (3.4 7 3.7, 3.2 7 3.7, and 3.4 7 3.4, respectively) had a differential predictive value on the rate of early discontinuation for depression with divalproex, lithium, or placebo. For the whole sample, a higher number of previous depressive episodes (OR ¼ 1.30 [1.055, 1.598] per category, df ¼ 1, P ¼ 0.014) and psychiatric hospitalizations (OR ¼ 1.68 [1.100, 2.577] per category, df ¼ 1, P ¼ 0.017) were associated with early discontinuation for depression.
Time to Depressive Relapse
Time to depressive relapse tended to be longer in the divalproex group than in the lithium group (Wilcoxon w 2 ¼ 3.11, df ¼ 1, P ¼ 0.08) . For the subset of 142 patients who responded to divalproex during the open phase, time to depressive relapse was longer among those randomized to divalproex (n ¼ 71) than to lithium (n ¼ 41, Wilcoxon w 2 ¼ 4.72, df ¼ 1, P ¼ 0.03). Time to depression for placebo-treated patients (n ¼ 37) did not differ from that of randomized divalproex-or lithiumtreated patients (Figure 2 ). Time to depression for patients who were open-phase lithium responders did not differ among groups (n ¼ 79 divalproex, n ¼ 32 placebo, or n ¼ 31 lithium).
Among patients with previous psychiatric hospitalization, time to depressive relapse was longer in the divalproex group (n ¼ 100) than the lithium group (n ¼ 57, Wilcoxon w 2 ¼ 5.93, df ¼ 1, P ¼ 0.01) (Figure 3 ), but did not differ between the divalproex and placebo (n ¼ 56) groups (Wilcoxon w 2 ¼ 0.80, df ¼ 1, P ¼ 0.37). Among patients without prior hospitalization, no significant treatment differences existed for time to depression. 
Predictors of Depressive Relapse
Predictors of Worsening of Depressive Symptoms
Worsening of depressive symptoms (measured by the mean change in DSS score from baseline) was positively related to the lifetime number of manic episodes (slope ¼ 0.68, df ¼ 1, P ¼ 0.015) and the number of psychiatric hospitalizations (slope ¼ 1.46, df ¼ 1, P ¼ 0.015). It was negatively related to baseline DSS score (slope ¼ À0.39, df ¼ 1, P ¼ 0.002). Therefore, the more manic episodes or hospitalizations patients had in their lifetime, the more likely they were to experience worsening of depressive symptoms during the maintenance phase. The mean DSS scores increased more among lithium-treated than in divalproex-treated patients (difference in mean change: 2.37, df ¼ 1, P ¼ 0.04).
DISCUSSION
In these analyses of the maintenance efficacy of divalproex, lithium, or placebo for bipolar depression, several clinically relevant findings emerged. Fewer divalproex/SSRI-treated patients than placebo/SSRI-treated patients terminated early for depression. Relatedly, divalproex/SSRI-treated patients remained in the study longer and took SSRIs longer than placebo/SSRI-treated patients. Divalproex was more effective than lithium in delaying time to depressive relapse among patients who responded to divalproex in the open period. Divalproex was more effective than lithium in increasing time to depressive relapse in patients with an indication of more severe illness (patients with past psychiatric hospitalization). Divalproex-treated patients had less worsening of depressive symptoms than lithium-treated patients. Finally, severity of prestudy course of illness predicted worse outcome for all treatment groups. The combination of divalproex and SSRI was an effective treatment for breakthrough depression. In contrast, SSRI without a mood stabilizer (divalproex) was ineffective. These are the first data from a randomized, blinded trial indicating that an antidepressant alone is inferior to an antidepressant plus a mood stabilizer in preventing breakthrough depression with bipolar disorder during maintenance treatment. The lithium and SSRI group was intermediate, but did not differ significantly from the placebo and SSRI or the divalproex and SSRI groups, perhaps because of Type II error caused by lack of high enough power in the placebo and lithium groups.
According to Kaplan-Meier analysis, time to depressive relapse was longer for divalproex-treated patients with previous psychiatric hospitalization, suggesting that divalproex may be more efficacious than lithium in maintenance treatment of more severe forms of bipolar illness. Better response to divalproex among patients who responded to divalproex in the open phase indicates that a positive acute antimanic response to divalproex may predict subsequent prophylaxis of depression with divalproex, but not with lithium. The patients who responded to lithium treatment in the open phase provided a similarly enriched sample to Divalproex in bipolar depression L Gyulai et al study the relative efficacy of randomization to continued lithium, compared to randomization to placebo or divalproex. No significant differences emerged, nor did numerical responses tend to favor the response of those randomized to lithium. In the light of these results, although limited by the smaller lithium sample size, the value of continuation of lithium from acute treatment for mania to maintenance treatment aimed at the prevention of depressive relapse requires further study. The duration of crossover from open phase to randomized medications did not affect the study outcome . History of psychiatric hospitalization had a discriminative effect on the efficacy of maintenance treatments, but no other baseline demographic, clinical, or prestudy clinical course variables had differential predictive value for response of depression to divalproex, lithium, or placebo. However, for the ITT sample, indices of severity (greater lifetime number of hospitalizations, manic episodes, and/or depressive episodes) predicted worse outcome across all treatment groups in terms of early discontinuation for depression, depressive relapse, and depressive symptom severity. We believe this is the first study to suggest that the lifetime number of manic episodes is associated with continuing depressive morbidity in bipolar disorder. This finding suggests that control (or lack of control) of mania may affect the depressive side of bipolar disorder. Supportive of this finding, others have observed that, during lithium treatment, a greater lifetime number of affective episodes (Gelenberg et al, 1989; Harrow et al, 1990; Gitlin et al, 1995; Tohen et al, 1990) or hospitalizations (O'Connell et al, 1991; Harrow et al, 1990 ) predicts more affective symptoms (O'Connell et al, 1991) or higher rate of affective relapse (Prien et al, 1974; Gelenberg et al, 1989; Harrow et al, 1990; Keller et al, 1992; Aagaard and Vestergaard, 1990) . However, predictors for the prophylaxis of depressive morbidity in controlled maintenance studies have not been previously reported.
Female patients were at a greater risk for major depressive relapse and therefore were more likely than males to be treated with antidepressants. Thus, females seem more prone to bipolar depressive episodes and may need more vigilant management for early detection of impending depression, despite the fact that they may not have a greater risk for interepisodic depressive symptoms than males. Aagaard and Vestergaard (1990) also noted that females were less responsive to lithium treatment than were males.
Limitations of this study have been described in previous publications (Bowden et al, 1997 Baldessarini et al, 2000) . To summarize, survival analysis of time to depressive relapse in the ITT sample showed no treatment differences. This may be explained by three factors. First, the a priori criteria for depressive (and for manic) relapse set for this study required a full depressive (and manic) episode . The relatively stringent definition that we used lowers the number of failure events, thereby lowers power and less generalizable to clinical practice. Other recent maintenance studies in bipolar disorder have defined depressive relapse less stringently as time to the treating psychiatrist's decision that additional therapy for depression (or mania) was required Bowden et al, 2003, Greil and Kleindienst, 1999) . On the basis of these recent studies, defining mood failure events as the time of intervention increases the practicability of placebo-controlled maintenance studies and is consistent with clinical practice of endeavoring to intervene early.
Second, and relatedly, the proportion of placebo-treated patients relapsing with depression in this study (28.3%) was apparently lower than in previous double-blind, placebocontrolled, parallel design studies of lithium (approximately 44-50%) (Fieve et al, 1976; Prien and Klett, 1973b) . Unlike the earlier lithium studies that abruptly discontinued lithium from stably maintained patients at the point of randomization, patients taking lithium in the open phase of this study were tapered off over a 2-week period, possibly reducing withdrawal-related relapse rates . The low placebo relapse rate reduced the effect size, thereby decreasing the probability of detecting differences between the active treatment groups and the placebo group. Third, the rate of affective relapse for placebo-treated (but not lithium-treated) patients has been previously shown to continue increasing after 12 months (Prien et al, 1974) ; thus, a longer randomized period might have produced more power to show differences between response rates to active medications and placebo.
Negative findings regarding the efficacy of lithium vs placebo must be viewed cautiously, especially in the light of the relatively low relapse rate on placebo in this study and continued evidence of maintenance efficacy of lithium in bipolar disorder (Gelenberg et al, 1989; Berghofer et al, 1996; Tondo et al, 1998; Bowden et al, 2003) . Furthermore, clinical variables such as episode sequence (Kokopolus et al, 1980; Maj et al, 1989) , frequency of mood cycling (Dunner and Fieve, 1974; Bowden 1995; Denicoff et al, 1997) , presence of mood-congruent or -incongruent psychotic features of the index episode (Greil et al, 1998; Tohen et al, 1992) , comorbid conditions (especially anxiety disorders) (Greil et al, 1998; Feske et al, 2000) , and family history (Grof et al, 1994) may provide further explanation of the differential response to lithium and divalproex. Some of these may need to be described in future studies as potential explanatory factors of treatment response.
In summary, this study demonstrates that divalproex improves several dimensions of depression during maintenance treatment of bipolar I patients who had experienced a recent manic episode at the point of study entry and reduces the probability of depressive relapse, particularly in patients with a more severe course of illness.
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